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1. Introduction 
The first significant use of mass spectrometry in clinical diagnosis was the determination of 
inborn errors of metabolism using gas chromatography coupled to mass spectrometry or 
GC-MS. Biologically significant metabolites such as organic acids, amino acids and others 
were usually extracted from biological fluids such as urine, and then derivatized to make 
them volatile, volatility being a prerequisite to separation by gas chromatography. Such 
elaborate extraction and derivatization schemes have made the use of GC-MS difficult for 
biologically significant molecules because of their thermal instability. Separations of 
thermolabile biological molecules by HPLC is a far more straight forward process than by 
GC and the coupling of HPLC with mass spectrometry, or LC-MS, was a major 
breakthrough in the application of MS to the measurement of biologically significant 
molecules such as those measured for clinical diagnosis. Since the late 1970’s there has been 
a great deal of research into coupling HPLC with mass spectrometry. Many different LC-to-
MS interfaces had been developed over the last 3 decades including the Moving Belt FAB, 
Thermospray, Particle Beam, and Flow-FAB, all of which no longer exist today. All these 
once quite promising and even popular techniques, have been replaced by those involving 
the use of atmospheric pressure ionization (API) which was first introduced commercially in 
the late 1980’s. The most prominent API LC-MS interfaces are Electrospray (ESI), Nebulizer 
Assisted Electrospray  (a.k.a. IonSpray), Atmospheric Pressure Chemical Ionization (APCI) 
using a Heated Nebulizer, and Atmospheric Pressure Photo Ionization (APPI) also using a 
Heated Nebulizer. API facilitated the rapid adoption of LC-MS and a good review of API is 
available by Thomson 1 and for clinical diagnostics using IonSpray by Henion 2. 
As the name implies, in API, ions are created at atmospheric pressure quite apart from the 
ultra-clean high vacuum analyzer. This means no analyzer contamination and no need to 
pump away potentially corrosive solvents and buffers using the MS system’s expensive 
vacuum pumps. This alone has made LC-MS coupling exceptionally rugged as well as 
keeping the operational aspects simple allowing those less skilled in instrumentation but 
more focused on applications to be successful. This led to a flourishing of bioanalytical 
applications such as the analysis of a wide variety of biomolecules including biopolymers 
like polysaccharides, DNA/RNA, proteins/peptides and a plethora of heretofore intractable 
small molecule analytes such as sphingolipids, phospholipids, acylcarnitines, amino acids, 
biogenic amines, nucleotides, saccharrides, polar and ionic pharmaceuticals, natural and 
exogenous metabolites, etc. 
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API techniques are defined as “soft” ionization methods producing primarily intact 
molecular or pseudo-molecular ions, i.e. ions are created without fragmentation. This 
presents a challenge in positively identifying compounds: one must subsequently employ 
tandem mass spectrometry (MS/MS) or high resolution/high mass accuracies or both to 
positively identify ionized species. Most clinical diagnostic applications today utilize 
MS/MS to identify and/or quantify trace analytes in complex biological matrices such as 
plasma and urine. Excellent review articles on this topic have recently been written by 
Dooley 3, Vogeser & Seger 4, and Shushan 5. 
The most successful and widespread use of MS/MS in clinical diagnosis is in the area of 
newborn screening for congenital disorders such as amino acidopathies, fatty acid oxidation 
disorders and organic acidurias employing close to a thousand instruments worldwide 6-9. 
Other popular applications in the clinical diagnostic field are: the therapeutic drug 
monitoring (TDM) of cocktail therapies such as anti-viral treatments 10-11 or 
immunosuppressents 12-14 or anti-cancer chemotherapies 15; the analysis of endogenous 
steroid hormone panels 16; the determination of peptide-based hormones especially where 
different isoforms are involved; and the screening and confirmation of drugs-of-abuse and 
toxicants 17-18. With respect to steroid analysis there has been an especially rapid adoption of 
MS/MS since there are now well documented cases of the superiority of LC-MS/MS assays 
versus immunoassays 19-21. The evidence of this superiority has led the American 
Endocrinology Society to issue a statement endorsing the use of LC-MS/MS for the 
measurement of low levels of endogenous steroids, such as testosterone in children and 
women, over traditional methods like immunoassays 22. There is a great deal of well 
founded interest in the application of MS/MS to endocrinology and the reader is also 
referred to a recent review article on this subject 23.  
In spite of the rapid advances made in the application of LC-MS/MS to clinical assays there 
are relatively few instruments employed in routine diagnostic labs compared to the 
traditional clinical analyzer systems which are based upon biochemical- and immuno-
assays. The advantages of LC-MS/MS are many including: no costly analyte specific 
reagents (ASRs); the ability to determine many analytes in a single run with the same low 
cost of analysis whether one or many analytes are determined; high specificity and 
sensitivity especially for small-molecule analytes in comparison to immunoassays; and 
relatively rapid assay development amenable to “homebrew”. There are however, 
significant disadvantages including: there are some classes of compounds, such as proteins, 
for which LC-MS/MS is not as sensitive as immunoassays; LC-MS/MS systems are 
complicated pieces of technology which require a great deal of training and skilled 
operators; the high capital cost of these instruments usually with no “reagent-rental” 
purchase options (no ASR’s); and finally, there is often a significant amount of pre-analytical 
sample treatment required frequently requiring external robotic liquid-handling systems. 
The above disadvantages are responsible for the relatively small uptake of LC-MS/MS into 
routine clinical diagnostic laboratories especially the latter where technicians are more used 
to simply loading instruments with samples without the requirement for sample pre-
treatment. 
2. Sample preparation 
Perhaps the most important facet of using mass spectrometers for clinical applications is the 
sample preparation procedure. Dealing with biological matrices presents many unique 
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challenges to performing mass spectrometry and, in particular, using liquid 
chromatography in conjunction with MS. Consideration has to be made for matrix 
interferences that produce undesired signals in the channels being monitored as well as 
dealing with ion suppression effects. Matrix interferences can take the form of isobars that 
have the same molecular weight and similar (but not identical) structures (e.g. steroids with 
the same molecular weight), structural isomers of the same compound (i.e. 3-epi-25-hydroxy 
vitamin D and -25-hydroxy vitamin D), fragmentation of metabolites back to the starting 
compound in the source (i.e. glucuronides fragmenting back to the hydroxyl precursor), 
source fragmentation of substrates to products (i.e. enzymatic profiling), or endogenous 
background materials that produce ions at the same masses as the compounds of interest. 
Ion suppression usually is from compounds that behave like a detergent or a surfactant such 
as endogenous fatty acids or formulation components like PEG or Tween. However; the 
suppression caused by the large amount of endogenous proteins or phospholipids found in 
the biological matrix are of primary concern. When analyzing small molecules (>1000 Da) by 
mass spectrometry the goal of the sample preparation is to remove as much of the proteins 
and lipids as possible. For large molecule analysis, such as proteins, isolating and purifying 
the peptide or protein usually must be done during sample preparation, and if not, lengthy 
chromatography must be used to separate the large number of compounds present in the 
biological matrix. 
2.1 Off-line methods 
Sample dilution to reduce the concentration of salts and endogenous materials is the 
simplest, but least efficient, method of sample clean-up. However, urine and saliva are 
relatively clean (compared to other biological matrices) and often the concentration of the 
analyte of interest is high enough (g/mL) that by simply diluting the sample by a factor of 
10 the matrix interferences are minimized enough that no further work-up is necessary. 
Protein precipitation is also very straight forward and easy to perform. In this case, an 
organic solvent or pH change is used that causes the proteins to denature and become 
insolvent. The proteins precipitate out of solution and can either be filtered out of the 
“crashed” solutions or are centrifuged and the supernatant is removed for analysis. If an 
organic protein denaturant is chosen, it must be miscible in water. Protein precipitation is 
used on all biological matrices including whole blood, plasma and tissue homogenates. The 
key to whether a protein precipitation alone will work is the solubility of the compounds in 
the organic crashing solution at the pH chosen. Extremely hydrophilic compounds may 
precipitate due to a lack of solubility. The most common solvents are methanol or 
acetonitrile.  Chilling the solvent will produce a more thorough clean-up. Typically at least a 
five to one ratio or organic solvent to matrix is required to “crash” the endogenous proteins, 
but 8 or 10 to 1 is preferred. Concentration of the sample can be done if the supernatant is 
dried and reconstituted in a smaller volume than the original sample. Another advantage of 
protein precipitation is that protein binding is destroyed when the proteins denature, so as 
long as the total faction of the compound of interest is being measured, one does not needed 
to worry about binding issues. If the free fraction is of interest, a different sample 
preparation method should be performed. The protein precipitation also destroys the 
enzymes present in the matrix, so for compounds that are susceptible to degradation due to 
enzymatic activity in the sample, protein precipitation will help with the overall stability of 
system. 
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Often the free or un-bound fraction of an analyte is desired. In this case one wants the 
compound bound to proteins to remain there (e.g. the analysis of free T4). Equilibrium 
dialysis or ultrafiltration is normally employed to measure the free fraction of an analyte. 
However, these methods can also be used to clean-up a sample since only molecules below a 
certain size can transport through the membranes. The majority of the biological matrix is 
usually large proteins that can not cross the membrane barriers and therefore the sample is 
cleaned for MS analysis. 
Liquid-liquid extraction (LLE) is based on partitioning of an analyte between two liquids that 
are immiscible. Typically, an organic solvent that is not miscible in water is chosen where the 
compound of interest has a high solubility. In this way, the compounds of interest are 
extracted from the aqueous matrix because they prefer to be in the organic layer of the 
mixture. The organic layer is then separated from the aqueous layer and can either be directly 
injected or dried leaving the compound of interest behind. Samples that are dried can then be 
derivatized or reconstituted as needed for analysis. The samples can also be concentrated if the 
final reconstituted volume is less then the starting sample volume. LLE is also very good at 
removing salts since they prefer to stay in the aqueous phase. The disadvantage of LLE is that 
it is labor intensive and has many steps that can introduce experimental error. The process has 
been made more palatable with the advent of automated liquid handling systems, but there is 
a lot of hazardous waste material generated and there is a significant cost associated with all 
the disposable materials used in the process. 
Solid-phase extraction (SPE) works in a similar fashion to LLE but the partitioning is 
between a solid and a liquid phase. SPE applies the same basic principles used in 
chromatography. Analytes of interest are absorbed to the solid phase during the clean-up 
step, which is usually under aqueous conditions. Under the right conditions, most of the 
matrix components will not be absorbed during the cleaning step and the analyte of interest 
is thus removed from the matrix. However, compounds with similar chemical properties to 
the analyte of interest are retained as well. Samples are then released or eluted from the 
solid phase with an organic solvent. The combination of the right pH and organic content 
can make the eluted solvent clean of all but a few relatively similar components, of which 
the analyte of interest is one. The process is completely automatable and has significantly 
less waste materials and cost then LLE. Once again, the samples can be directly injected or 
dried. Samples that are dried can then be derivatized or reconstituted as needed for analysis. 
The samples can also be concentrated if the final reconstituted volume is less then the 
starting sample volume and the process removes the salts from the sample. 
2.2 On-line methods 
Solid-phase extraction methods have also been developed on-line. In the majority of cases 
these methods employ two columns run in tandem, though single column methods exist. 
For two column approaches, the first column is an SPE column and the second is a normal 
HPLC column. Matrices are injected onto the HPLC system and samples are cleaned-up on-
line because the analyte is retained on the SPE column while the unretained material is 
washed to waste. Once the analyte of interest has been extracted from the sample matrix, the 
analyte is eluted to a second analytical column for analysis. The process is done with either 
disposal cartridges that are changed after each sample injection, or with columns that are 
cleaned between each injection by the mobile phases. In both cases the on-line methods have 
the advantage of direct injection and elution of the analyte, which removes the time 
consuming off-line steps of evaporation, reconstitution, and preparation. Therefore, on-line 
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methods are more efficient, fully automated and require far less consumables then their off-
line counterparts. An example of a two column on-line SPE configuration is shown if Figure 
1. Isocratic focusing is often used to gain better peak shape with dual column methods. In 
this case the percent organic used to elute sample from the clean-up column is teed into a 
aqueous LC flow from a second pump to reduce the amount of organic the analytical 
column sees during the transfer step. The samples are focused at the head of the analytical 
column by the isocratic aqueous make up flow from the second pump making hydrophilic 
compounds easier to capture. Figure 2 illustrates the configuration used for “isocratic 
focusing”. 
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Fig. 1. Dual Column Method Configuration (A) Sample load and Clean-up  
(B) Sample Elute 25. 
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Fig. 2. Isocratic Focusing Method Configuration (A) Sample Clean-up (B) Sample Transfer 
(C) Sample Elute 25. 
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Turbulent flow chromatography (TFC) is a second on-line methodology that is performed in 
a similar manner to SPE. The difference is in how the samples are separated from the matrix. 
Unlike traditional laminar flow HPLC systems, where the interaction between the stationary 
phase and the analytes is diffusion controlled, mass transfer is the primary mechanism of 
separation for turbulent flow. Since the diffusivity of a molecule is inversely proportional to 
its molecular weight, small molecules have high diffusivity and ready transport into the 
pores of a packed column under turbulent flow conditions. Large molecules, such as 
proteins, have low diffusivity and do not have time to enter the pores under turbulent flow 
conditions. The result is that large molecules are swept away by the turbulent flow while 
small molecules bind to the stationary phase inside the pores of the packed columns. 
Traditional it was necessary to use high flow rates to achieve turbulent flow (4-5 mL/min), 
but 0.5 mm ID TurboFlow® columns are available that reach turbulent velocities at 1-1.5 
mL/min. The molecular weight of the molecules excluded from the stationary phase can be 
adjusted by flow velocity. Figure 3 illustrates the effect of flow rate on the molecular weight 
exclusion using TFC 24. Since the primary matrix interferences are due to matrix proteins, 
separation of proteins in the biological matrix from the analyte of interest is the primary 
goal of online sample clean-up methods. In fact, when reading the literature on SPE it is 
often found that much better results are obtained at high flow rates (2-4 mL/min). This 
author believes that the higher flow rates achieve turbulent flow in the SPE column, even 
though they were not designed to do so, resulting in a far better mechanism for clean-up 
then the SPE partitioning alone. A comparison of the effects of ion suppression from protein 
precipitation, SPE and TFC is shown if Figure 4 25. 
 
 
Fig. 3. Comparison of Molecular Weight Exclusion of Proteins by Turbulent Flow 
Chromatography as a Function of HPLC Flow Rate 24. 
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Fig. 4. Ion Suppression Effects from, Blank Injection (50/50 methanol:water), Injection of 
Protein Precipitated Rat Plasma (4:1 methanol: plasma, centrifuged ), Injection of Extracted 
Rat Plasma in 50/50 methanol water, and TFC of Neat Rat Plasma 25. 
Another advantage of the two column methods is that they allow the use of multiplexing, 
which takes advantage of the time spent cleaning one sample to elute another. Two or more 
injections are staggered in time and can either have a selection valve that can divert multiple 
HPLC systems to a single MS, or has two clean-up columns where one is eluting to waste 
(clean-up) while the other is eluting either directly to the MS or to the MS through an 
analytical column (analysis). Figure 5 illustrates how multiple injections can be staggered in 
time to increase sample throughput. Samples are eluted to the mass spectrometer only 
during the part of the run when the analyte of interest in being eluted. During the HPLC 
method, when the samples are being cleaned, columns are being washed, or the systems are 
being equilibrated, flows from other streams are directed to the MS taking advantage of the 
time needed to perform these functions while not wasting any time on the mass 
spectrometer acquiring data when there is no analyte of interest eluting. 
Restricted access media (RAM) is a third on-line column approach to sample clean-up that 
can handle neat biological matrices. The particles packed into a RAM column are designed 
to restrict the access of large macromolecules to the adsorption sites of the stationary phase 
by coating the normal HPLC packing materials with a second bonded phase that allows 
small molecules through but repels or excludes large molecules. The cleaning of the sample 
from the matrix is similar to the mechanism of TFC but accomplished in a different way 
under laminar flow velocities. However, since the barrier is physical rather then kinetic, 
RAM columns tend not to last as long as other on-line columns because the restricting layer  
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Fig. 5. Staggered multiple inlet methodology (Multiplexing) of several HPLC systems to a 
single mass spectrometer. 
gets clogged over time. A comparison of TFC, SPE and RAM as a function of molecular 
weight exclusion of proteins is shown if Figure 6 24.  
Immunoaffinity extraction (IAE) uses antibody-antigen interactions to capture analytes with 
very high selectivity. Antibodies are immobilized onto the stationary phase of an LC column 
to effect the removal of the sample matrix while leaving the antigen behind. The antigen is 
then released from the column for analysis. Often these antibodies will interact with a class 
of compounds rather then only a specific analyte. However, the cross reactivity of similar 
compounds are much easier to analyze then the original matrix. One of the primary 
drawbacks to clinical analyzers that do not employ LC/MS/MS is that the detectors can not 
separate the interferences from the cross-reactivity. The added dimension of separating 
analytes by their molecular weight allows MS to distinguish compounds within the same 
class from one another greatly improving the accuracy of the measurement. IAE can also be 
performed off-line similar to the way SPE is done both off-line and on-line. A problem with 
IAE columns is that they tend not to have long life times and are quite expensive. 
2.3 Derivatization 
Often it is desirable to derivatize an analyte in order to improve the sensitivity or assay 
performance. In GC/MS or LC/MS, derivatization is used primarily to improve the  
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Fig. 6. Comparison of the Molecular Weight Exclusion of Proteins at 1.5 mL/min Flow Rates 
for Turbulent Flow Chromatography (TFC), Restrcted Access Media (RAM), and Solid 
Phase Extraction (SPE) Clean-up Columns. 
chromatographic separation or increase the ionizability of an analyte. Organic acids tend to 
give board diffuse peaks by HPLC due to ionic interactions with the stationary phase. Low 
molecular weight compounds that are very hydrophilic, like amino acids, tend not to be 
retained on most reverse phased HPLC systems. Converting the acids to an ester not only 
removes the ionic interactions of the acids but also makes the compounds more 
hydrophobic resulting in stronger retention. The most common derivatization for both 
organic acids and amino acids is to form the butyl-ester by reaction with acidic butanol 26-28. 
The enhanced chromatography results in better peak shape and better sensitivity. The 
sensitivity increases because the peaks are narrower, and the analytes elute with more 
organic in the mobile phase, which promotes desolvation in the source. In other cases, the 
chromatography is good but the compound just doesn’t ionize well. Adding a functional 
group that promotes ionization can dramatically increase sensitivity. Vitamin D is often 
derivatized with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) to increase sensitivity 29-30. 
Drugs of abuse screening is usually preformed by hydrolyzing the samples. The hydrolysis 
converts all phase two metabolites back to their precursors increasing the likelihood of 
detecting small concentrations by summing the signals from several sources of the drug into 
one signal. 
The majority of the derivatization preformed in a clinical laboratory is done off-line, is labor 
intensive, and is time consuming. However, automated liquid handling system can be used 
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to automate the derivatization. If fast kinetics exists, the derivatiztion can be performed on-
line. One issue with derivatization is determining how complete the reaction is and what 
affect that has on what is being measured. 
3. Clinical diagnostis 
3.1 Vitamin D 
Vitamin D deficiency has been linked to several skeletal disease conditions 31-32 prompting 
an increase in laboratory testing of serum vitamin D levels over the last several years. The 
Mayo Clinic has reported increases in vitamin D testing of over 80% per year 33. In fact, 
Vitamin D analysis is easily the most frequently used LC/MS/MS assay in the clinical 
laboratory today. 
In order to understand vitamin D analysis, it is important to distinguish the various analogs 
of vitamin D that are analyzed and their relationship and functions, since different 
laboratories perform the analysis by different methodologies. Figure 7 illustrates the 
nomenclature for the physiologically relevant vitamin D analogs. Both vitamin D3 and 
vitamin D2 are active, and while both can be absorbed from diet, only vitamin D3 can be 
made in vitro from exposure to UV light. The active form of vitamin D is the 1,25-
hydroxyvitamin D metabolite, but historically it has been difficult to measure. Therefore, the 
primary measurement in the clinically laboratory has been the 25-hydroxyvitamin D 
metabolites because they have higher circulating serum levels and much longer half lives. 
 
 
Fig. 7. Vitamin D nomenclature. 
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Vitamin D3 (cholecalciferol) is endogenously produced from 7-dehydrocholesterol in the 
skin from exposure to UV radiation at 290-315 nm. A pre-vitamin D precursor is formed that 
rapidly isomerizes to Vitamin D3. Significant variability in the amount of vitamin D3 
produced in this manner is observed because of differences in sun exposure due to climate 
and/or social behavior 34-35. Both vitamin D2 (ergocalciferol) and vitamin D3 are present in 
food such that diet becomes a significant factor in disease on-set and prevention. Dietary 
supplements for both vitamin D2 and D3 are available as well. 
To become physiologically active, both vitamin D2 and D3 must be metabolized. While there 
are several inactive metabolites, it is the 1,25-dihydroxyvitamin D that is active with the D3 
analog having about twice the activity of the D2 analog. To form 1,25-dihydroxyvitamin D,  
vitamin D is first metabolized to 25-hydroxyvitamin D by the liver. The kidney then 
metabolizes the 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D. Regardless of which 
form of Vitamin D is present, most of the circulating Vitamin D is bound to vitamin D 
binding protein (DBP). 
Clinically, the total amount of 25-hydroxyvitamin D2 and D3 is usually reported. There are 
several reasons both analytically and physiologically for evaluating the 25-hydroxy 
metabolites. First is that both vitamin D2 and D3 have short half-life times (t1/2) in circulating 
blood of 24 hours so their concentrations are greatly influenced by recent sun exposure and 
diet. Therefore, someone who is vitamin D deficient that just happens to go out in the sun 
for few hours right before their test would appear to be okay. The 25-hydroxyvitamin Ds 
have t1/2 of 3 weeks and; therefore, are much more representative of the individuals overall 
vitamin D levels. Several authors have made the case that only the 1,25-hydroxyvitamin D 
levels are important since that is the active moiety. There is laboratory testing available for 
1,25-hydroxyvitamin D but the analysis is more difficult, requires larger sample volumes, 
the t1/2 is only a few hours (though exposure to sun light and diet are no longer regulating 
factors), and the complexity of the sample preparation takes more time and resources 
making the assay less cost effective. However, for certain indications the analysis 1,25-
hydroxyvitamin D is clearly more useful, such as patients with chronic renal failure, vitamin 
D dependent rickets, 1,25-hydroxyvitamin D intoxication, lymphoma, and hyper or hypo 
parathyroidism 33. 
Historically 25-hydroxy vitamin D levels were measured using immunoassays. 
Immunoassays are unable to distinguish between 25-hydroxy vitamin D2 and D3 such that 
only the total 25-hydroxy vitamin level is reported. The LC/MS methodologies are able to 
measure the levels of 25-hydroxy vitamin D2 and D3 separately so the contribution of each to 
the total can be determined, which is useful in diagnosing the effectiveness of supplemental 
treatment of vitamin D2 to patients that are vitamin D deficient. In addition, there are 
problems with protein binding in the immunoassays that produce results that are lower 
than the corresponding LC/MS assays 36-37. There is also some controversy as to whether 
immunoassays give accurate results due to nonspecific binding of other vitamin D 
metabolites and or matrix effects 38-40. Many experts consider LC/MS to be the most accurate 
method for vitamin D analysis 39, 41 but there is a lot of resistance to changing reference 
levels that were established by the previous techniques. 
Early attempts to run 25(OH) vitamin D by mass spectrometry was challenging due to the 
fact that it is lipophilic, which makes it’s difficult to ionize by API methodologies. 
Furthermore, fragmentation is also difficult with the loss of water being the only ion formed 
easily. Other fragment ions are formed at high collision energies; however, under these 
conditions, multiple fragment ions are formed such that no one particular ion is formed 
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with any reasonable abundance. Early attempts to over come the low ionizability of 25(OH) 
vitamin Ds involved various types of derivatization. Vreeken et al 42 and others 43-45 used a 
Diels Alder reaction to enhance sensitivity in API of 25(OH) vitamin D. The method also 
increased the mass of the 25(OH) vitamin Ds resulting in lower background interferences. 
Hiagashi et al 43-44 used a Cookson-type reagent to produce a 15 fold increase in the 
sensitivity over the native form for measuring vitamin D in plasma. However, these 
derivatization methods are time consuming and cumbersome. Improvements in the 
sensitivity of mass spectrometers in recent years have made it unnecessary to derivatize 
vitamin D in order to achieve the desired sensitivity. 
Once the mass spectrometers became sensitive enough to measure vitamin D at the 
concentration required for clinical analysis the main obstacle to LC/MS/MS becoming a 
routine method for clinic diagnostics was making it high throughput. Vogeser et al 46 
reported a rapid LC/MS/MS method in serum employing on-line solid phase extraction 
(SPE) with a run time of 9 minutes. Chen et al 47 improved upon this method and reduced 
the total run time to 7 minutes. Knox et al 48 used protein precipitation followed by off-line 
SPE to run 160 samples per day. The off-line methods produce much faster LC/MS/MS run 
times but require more preparation in advance. However, these methods can be automated 
making them an attractive alternate. Hojskov et al 49 used protein precipitation followed by 
liquid/liquid extraction to get the total run times down to 4 minutes. However, the biggest 
improvement in sample throughput was realized by combining on-line sample clean-up 
with multiplexing capabilities. Taylor et al 50 demonstrated the use of on-line clean-up using 
turbulent flow chromatography with a Cyclone column and a Cohesive Technologies (now 
part of ThermoFisher Scientific) TX4 multiplexing system to get a sample throughput of 40 
samples per hour. Turbulent Flow allows fast and efficient on-line clean-up of biological 
sample while multiplexing allows coupling of multiple LC systems to a single mass 
spectrometer, greatly reducing time between injections. Several other authors have reported 
increased sensitivity in addition to increased sample throughput using TX2 or TX4 on-line 
multiplexing systems 51. Vitamin D analyses on these systems are routinely running 
injection to injection times of one minute (60 samples per hour). Table 1 summarizes the 
current LC/MS/MS vitamin D assays found in the literature. 
3.2 Immunosuppressant drug monitoring 
Therapeutic drug monitoring of immunosuppressant drugs (ISDs) is well established 56. The 
importance of monitoring these drugs is due to their narrow therapeutic window. Elevated 
dosing of the immunosuppressant drugs can cause significant toxicity while under dosing 
can result in transplant rejection. Because of this narrow therapeutic window, the 
immunosuppressant drugs are considered critical dose drugs, requiring individualized drug 
therapy by measuring the actual drug concentrations in each patient to maximize the 
therapeutic response and minimize adverse side effects. 
Currently there are two main choices in the clinical laboratory for monitoring 
immunosuppressant drugs; immunoassay or chromatography. However, issues with non-
specific binding of the antibody resulting in over estimation with immunoassays 57-60 as well 
as the long sample run times, complicated sample preparation procedures and lack of 
sufficient chromophores with HPLC-UV detection 61-63, have made LC/MS/MS 
methodologies the assay of choice when available. Most of the large-scale Contract Research 
Organizations (CROs), which operate as central laboratories for clinical diagnostics, analyze 
immunosuppressents by LC/MS/MS 57, 64. 
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    Sample Prep    
Reference Analyte Matrix PPT Extraction Derivatization Run time date 
Higashi (43) 
25(OH)D2 and 
25(OH)D3 
human plasma ACN LLE (AcOEt) DMEQTAD 7 min 2001 
Higashi (45) 
25(OH)D2 and 
25(OH)D3 
human plasma ACN LLE (AcOEt) NPTAD 7 min 2003 
Vogeser (46) 25(OH)D3 human serum ACN on-line SPE  9 min 2004 
Singh (52) 
25(OH)D2 and 
25(OH)D3 
human serum ACN TFC  7 min 2006 
Chen (47) 
25(OH)D2 and 
25(OH)D3 
human serum ACN on-line SPE  7 min 2008 
Knox (48) 
25(OH)D2 and 
25(OH)D3 
human 
serum/plasma
MeOH off-line SPE  5 min 2009 
Bunch (51) 
25(OH)D2 and 
25(OH)D3 
human serum ACN TFC  3 min 2009 
Newman 
(53) 
25(OH)D2 and 
25(OH)D3 
dried blood 
spots 
MeOH 
LLE 
(hexane) 
 10 min 2009 
Eyles (54) 
25(OH)D2 and 
25(OH)D3 
dried blood 
spots 
ACN  PTAD 3 min 2009 
Hojskov 
(49) 
25(OH)D2 and 
25(OH)D3 
human serum ACN 
LLE 
(heptane) 
 4 min 2010 
Casetta (55) 1,25(OH)2D3 human serium ACN on-line SPE  18 min 2010 
Table 1. Selected Summary of LC/MS/MS Vitamin D Methods. 
The four primary immunosuppressant drugs analyzed today are Sirolimus, Tacrolimus, 
Everolimus and Cyclosporin A. Clinical Assay kits are available from several vendors for 
the analysis of these immunosuppressents. These Kits include all the controls, calibrators, 
sample preparation reagents, internal standards, columns and all the necessary instructions 
to perform the analysis. Table 2 summarizes the performance of the currently available 
assay kits for LC/MS/MS analysis of ISD’s. 
 
Drug Linear Range 
Cyclosprin A 10-2000 
Tacrolimus 1-50 
Everolimus 1-50 
Sirolimus 1-50 
Table 2. A Summary of the Current Analytical Ranges for Immunosuppressant Drugs 
CV/IVD Kits. 
Both electrospray ionization (ESI) and atmospheric chemical ionization (ApCI) are used to 
analyze the immunosuppressents. Usually the precursor ion is not the protonated molecular 
ion (M+H)+ but is formed from the ammonium adduct (M+NH4)+ produced by having 
ammonium formate or ammonium acetate in the HPLC mobile phases 65. The use of 
negative ions has also been reported for cyclosporine A and tacrolimus 66. ApCI has the 
advantage of producing fewer matrix effects but sensitivity is reduced due to more 
fragmentation in the source. However, most mass spectrometers available today have more 
then enough sensitivity to measure the ISD’s using either ionization method. The 
chromatography of cyclosporine A normally requires elevated temperatures be used on the 
columns to produce good peak shape. Column temperatures are normally between  
60-75oC. 
www.intechopen.com
 
Clinical Applications 
 
687 
Initial LC/MS/MS methods for the ISDs used off-line liquid-liquid extraction for clean-up 
or solid phase extraction (SPE) to isolate the drugs from the plasma 67-69. Off-line methods 
are rather tedious, involve many manual steps that each can be a source of error, and take 
time. Automated liquid handling systems are available to reduce the tedium and operator 
errors but most laboratories have switched to on-line sample preparation processes. The on-
line methods usually follow protein precipitation and are of two general types: two-
dimensional chromatography using turbulent flow or on-line SPE columns for matrix 
removal followed by a reverse phase HPLC analytical column to get good chromatographic 
peak shape 69; or direct injections that rely on the analytical column to effect suitable 
chromatographic separation 70-71. Sample run times using two-dimensional chromatography 
with as little as 1 minute per sample run times are achievable when combined with 
multiplexing systems 69. Whole blood analysis is the most common method used due to the 
high protein binding of the ISDs. Cell lyses and denaturing of the proteins to release the 
bound drug is accomplished by using an organic such as methanol or acetonitrile in 
combination with zinc sulfate 67-72. 
The importance of choosing the right internal standards has been demonstrated in the 
literature 73. The availability of stable labeled isotope internal standards is critical because 
the ISDs are known to be more susceptible to matrix effects 73-75 and co-elute with many of 
the commonly found phospholipids. A study on cyclosporine by Taylor et al 74 clearly 
demonstrated that the isotope labeled cyclosporine had better analytical performance then 
any other of the analogs of cyclosporine that were tested.  
3.3 Steroids 
Steroid analysis is used for diagnosing several endocrine disorders. Traditionally the 
measurement of steroids was accomplished with immunoassays and radioimmunoassay. 
However, as stated previously, recent studies have shown the use of immunoassays is 
problematic 76-79 suffering from a lack of specificity, limited dynamic range and matrix 
effects. In fact the use of immunoassays has resulted in poor clinical correlation of the  
test results and substantial disagreement between different manufacturers of the assay  
kits 22, 76-80. 
The first successful use of mass spectrometry to steroid analysis in the clinical laboratory 
was achieved with GC/MS 80-82. Significant improvement in steroid measurement was made 
because of the high resolution separation capabilities of capillary gas chromatography 
coupled to the high specificity of mass spectrometer. However, in order to get the required 
sensitivity for steroid analysis, low throughput, labor intensive derivatizations, and other 
sample preparation requirements resulted in GC/MS methodologies not becoming widely 
used as a routine technique for steroid measurement in the clinical laboratory. 
The development of LC/MS/MS over the last 15 years has made it the technique of choice 
for analyzing steroids because of the high specificity of the mass spectrometer, the 
separation capabilities of the liquid chromatography, its wide dynamic range, and the 
availability of simple sample automated preparation procedures. Steroid analysis is 
commonly performed from serum, plasma, urine and saliva. The choice of sample 
preparation procedure is somewhat dependent on whether increasing the concentration of 
the steroid is necessary for detection. If that is required, off-line LLE or SPE is desirable so 
that the reconstitution volumes are lower than the amount of starting matrix used; 
alternatively derivatization can be employed to enhance detection. Both these methods 
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require labor intensive methodologies and significant cost per sample that are not desirable 
in the clinical setting. All of methods outlined previously are used today including 
extraction from dried blood spots. Table 3 summarizes the current steroid assays found in 
the literature. 
 
Aldosterone 113, 81, 119, 120 
Androstenedione 81, 83, 96, 88, 117 
Androsterone-sulfate 90 
Corticosterone 114, 81, 83 
Cortisol 108, 112, 114, 81, 116, 83, 88 
Cortisone 108, 114, 116, 122 
11-deoxycorticosterone 114, 116 
11-deoxycortisol 110, 114, 81, 83 
21-deoxycortisol 114, 83 
DHEA 81, 96, 118 
DHEA-sulfate 81, 90 
Dihydrotestosterone 83 
Epiandrosterone sulfate 90 
Estradiol 101, 81, 82, 102, 121 
Estriol 82 
Estrone 101, 82, 102, 121 
17-hydroxyprregnenolone 110, 115 
17-hydroxyprogesterone 110, 114, 81, 83, 88, 117 
Pregnenolone 110 
Progesterone 81, 83 
Testosterone 109, 111, 81, 82, 83, 96, 117, 118 
Table 3. Steroid assay references. 
The biggest problem with analyzing steroids by mass spectrometry is that there are isobaric 
interferences and considerable cross talk due to the similar fragmentation patterns of other 
endogenous steroids. Figure 8 illustrates the complexity of the various steroid pathways. By 
looking at the molecular weights, the loss of water (which easily occurs in the source), and 
the isotopic distributions, it becomes obvious that there is the potential for a large amount of 
cross talk between the steroids in the mass spectrometer. Table 4 lists the possible cross talk 
channels between the steroids. Therefore, the use of chromatography becomes critical to the 
unambiguous measurement of the various steroids. 
Another issue with steroid analysis is protein binding. When the total amount of steroid 
present is desired simple techniques like protein precipitation easily release the bound 
steroid. However, if the free fraction measurement is needed, dialysis or ultra-filtration 
methods are usually used. It is possible to measure the free and total separately if the 
sensitivity of the method is sufficient to measure the lower levels of the free fraction. Great 
care must be taken not to release any of the bound protein if the unbound steroid is 
measured. 
Often it is more desirable to measure steroid panels rather then individual steroids. The 
advantage of steroid panel profiling is not just to simplify the analytical methodology, but 
monitoring multiple steroid pathways often has clinical relevance 83-87. Diagnostics for CAH 
www.intechopen.com
 
Clinical Applications 
 
689 
 
Table 4. Mass interferences between the steroids. 
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Fig. 8. Complexity of the steroid pathways. 
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and PCOS, fertility treatment, tumor location, and patient monitoring after gonadal or 
adrenal surgery are routinely performed by LC/MS/MS 88-90. 
Measurement of adrenal steroids is important for the differential diagnosis of CAH and 
evaluation of adrenal function. The CAH panel includes the following steroids; 17OH-
progesterone, androstenedione, cortisol, adrenocorticotropic hormone (ACTH) and 
pregnenolone. Congenital adrenal hyperplasia is characterized by elevated levels of ACTH, 
which is the most common disorder associated with the assay. Cross reactivity and poor 
clinical correlations are observed with immunoassays making agreement with LC/MS/MS 
methods difficult. Method specificity is also critical to the population being tested and 
LC/MS/MS has been shown to be much more reliable than other methods especially for 
newborns, infants and the elderly 83, 91-92. LC/MS/MS methods for CAH have much lower 
false positive rates 83, 91-92 than the immunoassays and have been adapted to saliva 93-96 and 
dried blood spots 91, 97, which are far less invasive sampling techniques then drawing blood. 
Measurement of testosterone in men is used to diagnose hypogonadism and to monitor its 
treatment as well as to monitor androgen suppression therapy during prostate cancer 
treatment. In women, testosterone levels are markers of alopecia, acne, hirsutism, 
osteoporosis, tumor screening, late on-set CAH, PCOS, and other endocrine and 
reproductive diseases 98. In children, testosterone is analyzed for gender assignment in 
infants with ambiguous genitalia, delayed onset puberty, and CAH 88-90. The analysis of 
testosterone is also complicated by the need to measure both the free and total testosterone 
levels. 
Immunoassays for testosterone work well for healthy normal men but their lack of 
specificity makes them unreliable for the low concentrations found in women and children 
76-78. Methods for testosterone that utilize LC/MS/MS have demonstrated accurate 
measurement down to 10 pg/mL 84, 86, 89-100. Diagnostic methods for others androgens by 
LC/MS/MS have been reported with similar results including dihydrotestosterone (DHT), 
androstenedione, and DHEA 84, 86, 89, 100-102. Methods for the androgens often require 
derivatization or large sample volumes. However, recent improvements in mass 
spectrometer sensitivity have allowed analysis without these requirements. 
Low concentration of estradiol in females is associated with disturbed puberty, 
oligoamenorrheam and menopause 88, 98. Estadiol suffers form the same issues discussed 
previously for steroids in that there are several endogenous and matrix-related 
interferences. Problems with cross reactivity with immunoassays is a major problem once 
again, making LC/MS/MS the method of choice analytically. Like testosterone, estradiol 
does not ionize well and often derivatization is performed with dansyl chloride or an amine 
containing sulfonyl halide 103-106. Two dimensional chromatography methods have been able 
to measure estradiol without the need for derivatization 85, 105. 
Another important steroid that is analyzed by tandem mass spectroscopy is cortisol. Cortisol 
measurement is used to diagnose adrenal hyperfunction (Cushing”s syndrome) and adrenal 
insufficiency. Cushing’s syndrome results from over expression of cortisol by the adrenal 
glad and can be caused by pituitary hyperplasia, cancer of the adrenal or pituitary gland, or 
production of ACTH outside the pituitary gland. Cortisol measurements are done in 
plasma, serum, salvia and urine depending on the diagnoses. 
3.4 Thyroid hormones 
Thyroxine (3,3’,5,5’-tetraiodo-L-thyronine or T4) and triiodothyroxine (3,3’,5-triiodo-L-
thyronine or T3) are tyrosine-based hormones produced by the thyroid gland that are essential 
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for regulation of cell metabolism. Both excess and deficiency of thyroxine can cause clinical 
disorders. Hyperthyroidism is caused by the over production of T3, T4 or both. The most 
common example is Graves’ disease in which both the T3 and T4 levels are elevated. 
Hypothyroidism is a result of T3 and T4 deficiency and is related to Hashimoto’s disease. Both 
hyper and hypothyriodism can be caused by diet form either not enough or too much intake of 
iodine. Many thyroids cancers result in the over or under production of T3 and T4 as well. 
T4 is produced in the thymus gland and is the primary circulating from of thyroid hormone. 
The T4 is converted to T3 by tissue deiodinases that remove iodine from the 5’ position of 
T4. T3 is the active thyroid hormone. Both T3 and T4 are extremely protein bound (>99%), 
which makes the measurement of the free amounts difficult. The free hormone is considered 
the clinically relevant concentration because it measures the amount available to the cells. 
Free thyroid hormone measurements require separation of the free hormone from the 
protein bound hormone. It is critical that the separation does not disturb the endogenous 
equilibrium 107, 123. Equilibrium dialysis (ED) is the preferred method 124-126 but ultrafiltration 
(UF) is also used 127-128.  ED is labor intensive, time consuming (overnight, 17-24 hrs), 
technically demanding, and expensive, which make it unattractive to all but the large, well 
equipped and well staffed clinical laboratories. UF is much less time consuming (30-40 min), 
easier to use and has better reproducibility, but is also prone to leakage through the UF-
membrane 124. 
The use of tandem mass spectrometry following ED or UF has overcome the issues 
associated with measuring thyroid hormones with immunoassays 129-139. The first T3 and T4 
assays to use tandem mass spectrometry were developed for GC/MS and isotope dilution 
129-131, 133, 139-142. These methods required extensive sample clean-up and derivatization. 
Development of LC/MS methods eliminated the need for derivatization and allowed the 
introduction of on-line sample clean-up, greatly increasing the ease of use and removing 
many sources of experimental error 125. 
4. Toxicology 
Analytical toxicology is the detection, identification and measurement of drugs, or other 
foreign compounds (xenobiotics), and their metabolites in biological specimens. 
Toxicological measurements in the clinical laboratory can be both quantitative and 
qualitative depending on what question needs to be answered. Therefore, unlike the 
previous discussions where only quantitative measurements were needed and triple 
quadrupole MS/MS is the preferred methodology, toxicology screening uses many more 
types of mass spectrometers on a routine basis. There are several areas of interest for 
toxicological screening. First is screening of a biological specimen to detect and identify 
compounds in patients admitted to the hospital with acute intoxication of unknown origin. 
Intoxication can result from using drugs of abuse, both known and unknown, from 
accidental expose to hazardous chemicals in the environment, from bacterial or viral 
infections, or from disease states that produce toxic compounds in vivo. Second is the 
screening for illegal drug use of known origins where intoxication has not occurred but the 
substances are regulated, like steroid use in athletes. In the US, there are also programs to 
monitor pain management for compliance of prescribed drug use. The later is mostly a legal 
issue to identify patients that take advantage of the medical system and to identify doctors 
that abuse their privileges and prescribe drugs in manners not consistent with medical 
doctrine. Third is therapeutic drug monitoring (TDM) and occupational/environmental 
toxicology. There is considerable overlap between all of the toxicological assays. 
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One issue with the use of SRM transitions is the presence of isobaric interferences. When 
only one SRM transition is used there may not be enough specificity in the MS to distinguish 
between isobars. Chromatographic separation of the isobars is often the easiest approach to 
resolving isobars. However sometimes it is not possible to separate isobars 
chromatographically or the time taken to do so is not optimal for laboratory throughput 
needs or the time to result required is too long for an emergency case. Interference during 
the analysis of tramadol by LC-MS/MS arising from ingestion of the antidepressant 
venlafaxine is an example of this problem 143. In order to overcome isobaric interferences, 
the use of multiple transitions for a single compound and the ratio between the signal 
intensities for each transition is used 144-146. The application of product ion ratios is obviously 
limited for compounds which do not fragment reproducibly. Interference may also arise 
from metabolites, or other compounds, which fragment or thermally degrade in-source back 
to the parent compound. In these cases, chromatographic separation is the only option, but 
since the metabolites tend to be more hydrophobic then the parent, it is not difficult to 
achieve. Therefore, to minimize the risk of interference, multiple transitions that avoid non 
specific transitions such as water loss or low molecular weight fragments should be used 
whenever possible. For compounds which do not fragment well, or have only one major 
fragment, interferences must be separated by the chromatography. 
In forensic and post-mortem toxicology, systematic toxicological analysis (STA) and general 
unknown screening (GUS) is the starting point from which further, targeted quantitative 
analyses follows. Good sensitivity and reliability on as wide a range of compounds as 
possible is required.  For many years GC/MS, despite the problems associated with larger, 
non-volatile and thermally labile compounds, was considered the best strategy for these 
analyses. The reproducibility of GC/MS ionization/fragmentation allowed for the 
development of comprehensive mass spectra libraries for reliable structural identification. 
There are no equivalent LC/MS spectral libraries due to poor instrument to instrument 
reproducibility of LC-MS fragmentation. Therefore, in house libraries are needed for LC/MS 
application of SRM methods 17, 147-157. SRM methods also suffer from the fact that only 
known compounds can be searched and that a limited number of transitions can be 
monitored at one time. For these reasons, a move toward full scanning instruments for 
screening for both known and unknown compounds is more practical 158-164. 
Information or data dependent acquisitions are used to find compounds above a 
background threshold when acquiring full scan data. Identification is accomplished by 
triggering MS/MS acquisitions on the precursor ions found above the threshold 1165-167. 
Linear ion traps, orbital traps, Qtraps and QTOF are better suited to full scan acquisitions 
because they acquire full scan data much faster and with no loss of sensitivity compared to 
triple quadrupoles. However, once the identity of a compound is known, the triple quad is 
still the best quantitative instrument such that screening is often done by ion traps but 
conformation and quantification is usually done by triple quads. 
An emerging approach to STA analysis is the use of accurate mass (exact mass, or high-
resolution) MS. Full-scan MS experiments with 0.1 mDa accuracy are possible that filter the 
full-scan data and extract analyte chromatograms with very low background noise. 
Compounds which have the same nominal mass, but different exact masses, can be resolved 
by the mass spectrometer 168-169. TOF-HRMS is of interest in the application of empirical 
formula-based data libraries, with isotope pattern-matching software, and the potential to 
screen for unknown compounds (and identify their metabolites) by knowledge of elemental 
composition alone, without the absolute need for reference material 170. Exact mass 
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identification of specific metabolites and systematic fragmentation approaches have shown 
that even structural isomers can be distinguished using accurate mass 169. Further, 
retrospective interrogation of full-scan data can be useful to investigate the presence of new 
compounds/metabolites (such as new ‘designer drugs’) without re-analysis. Newer 
Orbitrap®/Exactive™ technology (ThermoFisher Scientific), also capable of HRMS, is 
finding toxicologically relevant applications 171-173. “In house” library matching should be 
carried out for unequivocal compound identification because mass spectral libraries and 
compound databases may not be completely transferable between instruments. 
Furthermore, library data matching does not give any information about chromatographic 
retention time, which is just as important as the mass spectral information 156, 174-177. 
Examples of current assays preformed using tandem mass spectrometry for toxicology are 
listed in Table 5. 
4.1 New born screening 
Newborn screening programs are designed to identify disease states in infants due to inborn 
errors in metabolism or genetic defects before they become symptomatic. One problem as 
the ability to detect more and more disorders in newborns increases is that often there is no 
treatment for the disease. Researchers need to be cognizant of the implications of knowing a 
patient has a disease and not be able provide treatment. 
Newborn Screening (NBS) for metabolic disorders started in the 1960’s with a test for 
phenylketonuria using bacterial inhibition from dried blood spots 26. This method was 
used exclusively for phenylketonuria (PKU) for several decades without many additional 
aminoacidopathies being added. The beginning of the use of electrospray tandem mass 
spectrometry changed all that, heralding an explosion of new tests beginning in the mid 
1990’s where the development of high throughput screening from dried spots using ESI-
MS/MS was demonstrated for a large number of inherited metabolic disorders by several 
authors 26-27, 178-182.  Using ESI-MS/MS, PKU was determined from newborn dried 
bloodspots (DBS), taken between 24 and 72 hours after birth, by first extracting the amino 
acids then derivatizing phenylalanine (Phe) and tyrosine (Tyr) to form butylated esters. 
The butylation reaction was simple and quick making it easily adaptable to high 
throughput screening. The MS/MS analysis of butylated amino acids was very simple and 
specific and the use of isotopically labelled internal standards allowed for absolute 
quantification of the analytes in the DBS sample. Diagnosis of PKU was further improved 
by taking the ratio of concentrations of Phe to Tyr which is a more sensitive measure of 
the activity of the enzyme phenylanlanine dehydrogenase. The same 
extraction/derivatization and ESI-MS/MS methodology was then extended to diagnose 
other aminoacidopathies such as maple syrup urine disease, by forming and detecting the 
butylated esters of leucine, isoleucine, alloisoleucine and valine178. Once again, absolute 
quantification was made by the use of isotopically labelled internal standards for each 
amino acid tested. The same technology was then extended to methionine for diagnoses 
homocystinuria and hypermethiononemia179. 
In addition to amino acid screens, it was discovered that the butylation reaction was 
compatible with the simultaneous determination of acylcarnitines from the same DBS 
sample. The test for medium chain length acylcarnitines was thus developed and used to 
diagnose medium-chain acyl-CoA dehydrogenase deficiency (MCAD) 27, 180.  The added 
advantage that the tests for the amino acids and the acylcarnitines could be performed in the 
same 2 minute assay on the same DBS sample, meant that more then 30 different diseases 
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could be routinely screened by ESI-MS/MS including aminoacidopathies, organic acidurias 
and fatty acid oxidation disorders.  
One problem with performing amino acid analysis by MS is the inability to distinguish 
isobars such as Leu and Ile. Iosbars must be separated by the chromatography but that often 
can extend the run times making the method unsuitable for high throughput screening. 
Another issue with the use of butyl esterfication derivatives is that it destroys glutamine 
which is the best marker for ornithine transcarbamylase deficientcy (OTCD). Glutamine is 
mostly converted to the glutamic acid butyl ester during the derivatiztion and the remaining 
glutamine butyl ester formed is deaminated in the electrospray source 183. 
An alternative derivatization method that has been shown to produce more stabile ions then 
the corresponding butyl esters is the formation of formamidene butyl esters of amino acids 
28, 184. The method was further optimized to include glutamine and achieved an increase in 
sensitivity of 50% by forming the isobutyl esters instead of the n-butyl esters. Unfortunately 
this method can not be used as a substitute in new born screening assays because the 
acylcarinitines are not fully derivatized at room temperature with this reagent. 
In addition to amino acid and acylcaritine analysis, newborn screening is also preformed on 
free methylmalonic acid and 3-OH propionic acid using the butylated etser derivatization 
185. There are some authors attempting to remove the derivization step from the procedure 
but no routine screening is being done without it.  
Hypothyroidism, which was described previously, is also measured in routine newborn 
screening; however, the assay is usually performed using dried blood spots and an 
immunoassay to test for the thyroid stimulating hormone (TSH) 186. 
Lysosomal storage disorders (LSD) are a group of rare inherited metabolic diseases that 
result from deficiency or absence of specific enzymes that breakdown unwanted substances 
in cells. The resulting build up of undesirable materials leads to disability or death. 
Recently, treatment for some of the more abundant LSDs has made the need for screening in 
newborns necessary and is now required in several states and in many European countries. 
Even though the individual disorders have low incidence their combined abundance is 1 in 
3,000 187-191 warranting their screening in newborns. 
Screening for enzymatic deficiencies is done by incubation of samples, in this case dried 
blood spots, with an added substrate that is known to be converted to a specific product by 
the enzyme of interest. Normal patient samples will form the product because the enzyme is 
present. Patients deficient in the enzyme will produce much less or no product from the 
incubation. Measurement of the product formation over time is then used to diagnose those 
with enzyme deficiencies. 
The initial method for LSDs was designed to analyze Fabry, Gaucher, Krabbe, Neimann-
Pick and Pompe disease simultaneously and comprised a 24 hr incubation step prior to mass 
spectral analysis 187-191. The method was designed for quick LC/MS/MS analysis to facilitate 
high throughput and had a sample runtime (injection to injection) of 2 minutes. The draw 
back of the method was that in order to have fast analysis time on the mass spectrometer no 
real chromatographic separation was used. The result is that there were interferences from 
the substrates on the product ion spectra. To reduce the cross talk from the substrate, 
extensive off-line extractions are conducted to separate the substrates from the products. 
These extractions used a lot of materials increasing the cost, all the extra manipulation 
increases the odds of experimental error, and the process took an entire day to perform. 
More recently, a method that employs turbulent flow chromatography for on-line clean-up 
to remove matrix effects and UHPLC to separate all the substrates from all the products has 
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been reported by Kasper et al 190. This method is 4 minutes injection to injection but is 
multiplexed to reduce the system run time to 2 minutes per sample. Another advantage to 
the improved method is that the initial method needed to de-tune the ion source conditions 
to reduce fragmentation in the source to guarantee no signal from the substrates in the 
product ion channels. In doing this the authors also reduced the signal strength. The 
UHPLC step employed in the new method separates the substrates and products 
chromatographically such that no detuning is necessary. The result is that less product 
formation is needed and reduced incubation times are possible as well. Recently a sixth LSD 
was added to the LSD panel to screen for MPS 1 disease 191. Additionally, cost analysis 
comparing on-line TFC clean-up to off-line extraction methods calculated the total cost per 
sample for LSD screening to be 0.29 Euro using the on-line method and 0.96 Euro using off-
line extraction. 
Most of the disorders in the expanded or supplemental newborn screening list used today 
that are performed by mass spectrometry are shown in Table 10. This expanded screening is 
not yet universally mandated. 
4.2 Proteomics 
Barr et.al. 192 were the first to demonstrate the use of proteotypic peptides, usually tryptic 
peptides of proteins targeted for quantification, as quantifiable surrogate markers for the 
intact protein. Gerber et.al. 193 employed isotopically labelled proteotypic peptides and LC-
SRM. They called these peptides “AQUA” short for Absolute QUAntitation when 
employing these isotopicallly labeled peptides as internal standards (ISs) for quantifying the 
surrogate proteotypic peptides. The main advantage of this method of quantification is that 
the AQUA peptides are chemically identical to the proteotypic peptides making them ideal 
ISs since they coelute with the analyte of interest. This is important since both IS and analyte 
peptide are ionized and detected under identical conditions eliminating issues like ion-
suppression brought about by co-eluting matrix. The method of detection is SRM or selected 
reaction monitoring where the precursor molecular ion is transmitted by the first analyzer 
(“Q1” usually a quadrupole mass filter in a triple quad instrument), fragmented in the 
quadrupole collision cell (2nd quadrupole) and the appropriate product ion(s) are then 
monitored by the final quadrupole mass filter (“Q3”). The fragment ions formed are dictated 
by the proteotypic peptide’s amino acid sequence making the SRM process very specific for 
the analyte and corresponding IS. If more specificity is required, additional fragment ions 
can be monitored per proteotypic peptide. 
The group at the Plasma Proteome Institute improved this process adding an 
immunoaffinity step called SISCAPA (Stable Isotope Standards and Capture by Anti-
Peptide Antibodies), to concentrate the proteotypic and AQUA peptides enhancing their 
detection by LC-SRM 194. These SISCAPA techniques have evolved to where they now 
employ integrated systems incorporating magnetic beads coated with immunoaffinity 
agents implemented in low-volume trap-wash-elute apparatus suitable for the efficient 
transfer of highly concentrated analytes to low-flow LC-SRM systems. It is estimated that 
such systems are capable of enrichments of analytes up to 20,000 times providing detection 
limits of proteotypic peptides and the proteins they represent down to low ng/mL levels 
rivaling those of some ELISA assays 195. 
One significant advantage of this approach is that the cost of analysis of many analytes by 
LC-SRM is the same as that of a single analyte which could be especially important when 
multiple biomarker assays are employed. Anderson and Hunter 196 demonstrated the 
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principle where over 100 SRM’s were monitored in a single LC-SRM experiment 
representing the quantitation of over 50 proteins in a single assay. 
Certain immunoassays have poor performance due to a variety of factors including 
potential interference from endogenous immunoglobulins and imperfect concordance across 
platforms due to antigen microheterogeneity across patient populations 197. In such cases the 
performance of LC-SRM may have significantly better performance as described in the 
example using SISCAPA to quantify thyroglobulin, a well characterized tumour marker for 
which interference from endogenous immunoglobulins affects results for 10% to 25% of all 
patients. Thyroglobulin was successfully quantified down to picomolar levels (3 ng/mL) in 
non-depleted plasma by SISCAPA LC-SRM. One advantage of the assay is that the 
trypsinization step digests endogenous immunoglobulins that could potentially interfere 
with immunoaffinity. LC-SRM overcomes these serious problems exhibited by commercially 
available immunoassays for thyroglobulin. 
Carr 198 recently demonstrated that SISCAPA LC-SRM can be used to quantify a “panel” of 
protein biomarkers in plasma. In the present example plasma samples were taken at timed 
intervals during a planned myocardial infarction (PMI) used to treat hypertrophic 
obstructive cardiomyopathy. It was thought that these samples would be representative of 
myocardial infarction (MI) and that monitoring well recognized biomarkers of 
cardiovascular disease such as interleukin-33 (IL-33), for which there is no well-validated 
immunoassay, and cardiac tropinin I (cTnI) would provide insight into the pathophysiology 
of MI. The authors suggested that SISCAPA LC-SRM would be better suited to multiple-
biomarker assays since there is less likelihood of non-specific binding between the capture 
and detection antibodies. With SISCAPA each analyte (proteotypic peptide) requires only a 
capture antibody since the detection is done by LC-SRM. The results of the study indicated a 
poor correlation between the immunoassay for cTnI and SISCAPA LC-SRM. They 
speculated that non-specific interactions with endogenous antigens in the immunoassay 
could account for the poor correlations where LC-SRM would not be as susceptible to these 
interferences. Even though the SISCAPA LC-SRM exhibited impressive detection limits for 
IL-33 in spiked serum (low ng/mL), signals for endogenous levels of this analyte in plasma 
samples were below detection limits. Sensitivity is a common problem for the SISCAPA LC-
SRM approach where protein analytes are required to have plasma concentrations above the 
low ng/mL where many important protein analytes are present at pg/mL levels. 
There are some recent examples of the use of LC-SRM to determine endogenous protein 
biomarkers at higher concentrations. A group at Mayo used LC-SRM of proteotypic 
peptides to quantify serum Zn-ǂ2 glycoprotein (ZAG), a putative biomarker for prostate 
cancer 199. Serum samples were trypsinized without the need for the depletion of abundant 
proteins and relatively high flow-rate LC-SRM was used instead of nano-flow HPLC. The 
use of 2 mm ID HPLC columns and higher flow rates greatly enhances the ease-of-use of 
this method as well as ruggedness and reliability of the assay. Prostate cancer patients 
showed an average ZAG concentration of 7.6 mg/mL where control subjects had an average 
ZAG concentration of 3.7 mg/mL demonstrating a clear differentiation. The method itself 
was validated between 0.32 and 10.2 mg/mL. 
Another interesting example involves the determination of human serum albumin (HSA) in 
urine as a biomarker for renal failure. Renal disease is steadily rising as a complication of 
type-2 diabetes which is reaching epidemic proportions in North America. Urinary Albumin 
is a sensitive prognostic and diagnostic biomarker for renal disease. Early diagnosis of the 
onset of renal disease can prevent much more expensive interventions by giving patients a 
www.intechopen.com
 
Tandem Mass Spectrometry – Applications and Principles 
 
698 
chance to change diet or life-styles to avoid more serious manifestations of the disease. 
Accurate and precise methods of rapidly screening for renal disease will become important 
in population screening to avoid false positives and false negatives; such methods must also 
be inexpensive to permit their widespread use as disease-screening modalities. A group at 
the Mayo clinic 200 recently published a method for HSA in serum using LC-SRM and the 
detection of 2 proteotypic peptides representative of HSA and employing isotopically 
labeled AQUA peptides as ISs generated in a novel fashion. ISs were introduced into the 
serum sample as a precisely known amount of intact recombinant 15N-labelled HSA prior to 
tryptic digestion. During trypsinization both endogenous and labeled HSA forms are 
degraded into tryptic peptides where the 15N labeled peptides act as ISs for the endogenous 
HSA. The high flow rate LC-SRM method was validated over the linear range of 3 to 200 
mg/mL spanning the clinical requirements. HSA at these levels requires no 
preconcentration or nano-scale chromatography to be detectable. The run time, however, 
was 30 minutes making it too long for a population-screening modality. This long analysis 
time could be significantly shortened using multiplexed sample introduction as described 
above. The LC-SRM method compared well with immunoturbidity but without the need for 
sample dilution to cover the full analytical range like immunoturbidity requires. 
There is significant interest in the use of SISCAPA LC-SRM for the detection of proteins in 
biological fluids as evidenced by the following references by Ackerman and others 201-204. 
There have been multi-site trials to evaluate the reliability of these types of assays in various 
laboratories across different LC-SRM platforms 205. There is controversy as to whether such 
tests will be transferable to the clinical diagnostic laboratory given the complexity of these 
tests. This controversy was recently discussed in an article by Diamandis 206 based upon 
interviews of a panel of experts in the field. The consensus opinion was that MS will best be 
used in situations where good immunoassays do not exist and that the greatest application 
for LC-SRM will be in the validation of putative protein biomarkers; while this is not clinical 
diagnosis, this application cannot be undervalued. Over the past 15 years of intense 
proteomic research thousands of putative protein biomarkers have been identified in human 
plasma or serum, yet no significant increase in FDA-approved protein diagnostics has 
followed 207. Articles have been written decrying this terrible record and the blame lies with 
a lack of rigorous validation of putative biomarkers involving clinical studies of sufficiently 
large cohorts of patient samples. Such studies would require the high throughput 
quantitative analysis of trace protein biomarkers and there is much hope that MS-based 
quantitative techniques such as SISCAPA LC-SRM will help in this validation process 184, 208.  
One area where MS may also be very useful is for the determination of heterogeneous 
proteins whose isoforms respond similarly to the immunoassay but whose diagnostic values 
differ greatly. The sources of protein biomarker microheterogeneity could be genetic, 
environmental, or a mixture of both. This kind of variability in populations is precisely why 
large-scale multi-center clinical trials are performed on new diagnostic tests to ensure that 
this natural protein variability does not confound the interpretation of results. However, 
what is being ignored here is that the variability itself is likely a source of information about 
disease and possibly diagnostic of it. 
Nelson 209 and Niederkofler 210 pioneered the application of Mass Spectrometry Immuno 
Assays (MSIA) combining immunoaffinity of intact protein targets with a direct mass 
spectrometry readout usually using MALDI-TOF to determine the various protein 
isoforms captured by their proprietary immunoaffinity pipettor tips. This has led to some 
very informative and thought provoking observations of significant correlations of 
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protein variants and isoforms with disease states. Lopez and Nelson 211 combined MSIA 
with LC-SRM in the determination of PTH isoforms and their potential correlation with 
renal disease. The full length form of PTH secreted from the thyroid gland comprises 84 
amino acids referred to as PTH(1-84). The measurement of PTH(1-84) and its N-terminal 
truncated form PTH(7-84) are currently assayed to assist in the diagnosis of 
hypo/hyperparathyroidism and hypercalcemia and in monitoring for renal 
osteodystrophy in patients with end-stage renal failure. The PTH(1-84)–to–PTH(7-84) 
paradigm is a recent example of the biological and clinical utility of microheterogeneity 
within the PTH protein. These authors began their investigation with an MSIA MALDI-
TOF experiment that identified a significant number of PTH variants including the 
previously unidentified PTH variants PTH(28–84), PTH(34–84), PTH(37– 84), PTH(38–84), 
PTH(48–84), PTH(34 –77), PTH(37–77), and PTH(38 –77). Quantitative MSIA LC-SRM 
assays were developed for PTH(1–84), PTH(7–84) and the newly identified variant 
PTH(34–84), where immunoaffinity captured PTH isoforms were tryptically digested 
postcapture prior to analysis by LC-SRM using a variety or proteotypic peptides and their 
corresponding isotopically labeled analogues as internal standards. In all, 32 SRM 
transitions were simultaneously monitored throughout the analytical run. The peptides 
monitored by LC-SRM exhibited linear responses (R2 0.90–0.99) relative to recombinant 
human PTH concentration, limits of detection for intact PTH of 8 ng/L and limits of 
quantification of 16–31 ng/L depending on the peptide. Many of these peptides showed 
good correlations with renal disease and could be used as a basis for differentiating 
patients with renal disease from healthy controls. 
The determination of LSDs, as discussed above in the section on Newborn Screening, is 
basically the indirect determination of proteins (lysozomal enzymes) by monitoring the 
conversion of small molecule substrates into products. Many other newborn screening 
(NBS) methods are designed to assay proteins, usually from dried blood spots (DBS). The 
most well-known of these is the measurement of Thyroid Stimulating Hormone (TSH) by 
immunoassay. TSH concentrations from newborn blood spots are significantly below the 
detection limits of LC-SRM methods; however, there are some recent examples of how mass 
spectrometry can be employed to screen diseases in newborns employing the measurement 
of protein biomarkers. 
Wilson’s Disease (WD) is characterized by reduced ceruloplasmin (CP) levels in blood 
leading to abnormal transport of copper resulting in dangerous elevations of copper in the 
body's tissues. The excess copper damages the liver and nervous system and WD affects ca. 
1 in 30,000 newborns. Wilson's disease has an autosomal recessive pattern of inheritance 
characterized by progressive deterioration of the liver and the brain. Consequently liver 
disease and neuropsychiatric symptoms are the main features that lead to diagnosis. A 
significant percentage of those diagnosed with WD already require a liver transplant but 
relatively inexpensive effective treatments are available if diagnosed early 212-213. The 
measurement of intact proteins directly is often impractical by LC-MS because of their low 
concentrations such as TSH. As discussed previously, proteotypic tryptic peptides, which 
are surrogates for the intact protein, are much easier to detect and quantify by LC-MS/MS. 
This methodology was employed to determine CP extracted from DBS. The results of the 
study demonstrated clear differentiation between affected newborns, heterozygous carriers 
of WD and normal newborns. The levels of CP for the unaffected carrier newborns was ca. 
250 mg/L and in a cohort of affected newborns ranged from 10 to 20 mg/L. The 
LC/MS/MS method was rather lengthy for a newborn screening modality (ca. 7 min); 
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however, this could be made faster using a multiplexed multi-column system, as suggested 
by the authors. 
Hemoglobinopathies represent a tremendous opportunity for MS/MS. These are rare 
disorders but the combined incidence can be quite high and every jurisdiction in the USA 
and many others throughout the world test newborns for these disorders. Outcomes can be 
significantly improved if treatments are commenced early after birth. Currently used 
methods to detect hemoglobinopathies include ion exchange chromatography (IEX) and 
isoelectric focusing (IEF) both of which are time consuming and generally exhibit poor 
specificity when unusual post-translational modifications occur. Many articles have been 
published on the use of MS and MS/MS for the determination of hemoglobin (Hb) variants 
via molecular weight determinations on intact ǃ-globin chains 214-216. These techniques suffer 
from situations where the mutation involves a zero (nominal) mass change such as 
Lys↔Gln or Leu↔Ileu. Most labs use a combination of ESI-MS, IEX and IEF followed by 
DNA analysis to screen and confirm hemoglobinopathies. MS/MS analysis on its own using 
proteolytic (tryptic) peptides was suggested as a means of analyzing all mutations 214. 
Dooley was the first to suggest that all hemoglobinopathies could be screened and 
confirmed using only MS/MS of tryptic peptides derived from DBS extracts 217. Recent work 
by Dalton and Turner 218-219 demonstrated that MS/MS could be used to screen all the 
clinically important hemoglobinopathies including HbS, HbC, HbE, HbDPunjab, HbOArab, 
HbLepore, and ǃ-Thalassemia as well as other clinically important conditions such as delta ǃ-
Thalassemia, hereditary persistence of fetal hemoglobin trait (HPFH) and alpha zero 
thalassemia trait. The important finding of this work was that all these conditions could be 
screened in a 1 to 2 minute MS/MS experiment using SRM, monitoring 1 SRM per 
proteotypic peptide and employing proteotypic peptides of wild-type globins as 
endogenous internal standards. The method employed simple trypsinization of the DBS 
extract followed by a 1 to 2 minute flow injection analysis (FIA) MS/MS experiment ideal 
for high throughput screening. These authors demonstrated that by using SRM-triggered 
full scan MS/MS they were also able to confirm the amino acid sequence of the variant 
peptide without the need for costly genetic (i.e. DNA) analysis. It was demonstrated that 
confirmation could easily be built into the screening assay without paying a penalty in time 
or sensitivity. This work was validated by Boemer, et.al. 220 employing 2 SRM channels per 
proteotypic peptide and a different brand of MS/MS instrument. Both assays demonstrated 
100% sensitivity and specificity using this approach for a wide variety of 
hemoglobinopathies and even the ability to detect heterozygous genotypes. Dalton and 
Turner went on to perform a clinical trial 221 on a cohort of 40,000 newborns comparing 
MS/MS to the predicate IEF method. The results indicated complete concordance between 
the two methods detecting 199 HbS (including 8 HbS/HbF and 3 HbSC variants), 39 HbC, 
52 HbDPunjab , and 48 HbE. 
4.3 Metabolomics 
As discussed in the previous section, there has been almost 15 years of intensive proteomics 
research with relatively little to show for it in terms of novel protein diagnostics due mainly 
to a lack of biological validation of the putative diagnostic targets. Similarly, there is 
intensive research into metabolomics as a source of new disease biomarkers. Many of the 
putative metabolomic biomarkers are actually panels of endogenous metabolites for which 
mass spectrometry has been demonstrated to be very well suited as both a discovery and 
detection modality. 
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A recent review by Ellis 222 concluded that of all the “omics” areas of research to discover 
novel biomarkers, metabolomics is probably the most achievable. There are probably on the 
order of <5,000 metabolites 223 circulating in blood, where there are about 30,000 expressed 
genes with hundreds of thousands of single nucleotide polymorphisms (SNPs) and 
probably well over 1,000,000 proteins considering post-translational modifications and 
splice variants. With only several thousand metabolites that need consideration, 
metabolomics is likely to be a more achievable source of new diagnostics than either 
genetics or proteomics posing much less of a challenge to identify, quantify and validate 
diagnostic potential. Apart from their potential diagnostic value, metabolite-based 
biomarkers could also be useful in patient stratification in clinical trials or in disease-
treatment where it would be used to monitor whether patients are responding well or 
poorly to pharmaceuticals or even simple life-style changes. Just as in proteomics research, 
the majority of recent metabolomic work using mass spectrometry has concentrated on the 
discovery of novel disease-related biomarkers involving metabolome-wide studies 
(hundreds or even thousands of metabolites) on cohorts of only relatively few patients and 
controls. The result has been the creation of panels of many putative metabolomic disease 
biomarkers without the requisite clinical or biological validation involving broader 
population studies. To facilitate such studies one group in particular (an Innsbruck-based 
company called Biocrates, pronounced like “Socrates”) has developed CE-IVD approved 
kits that can be applied in anyone’s laboratory to economically perform these rigorously 
quantitative metabolomic validation studies across relatively large sample sets. Such studies 
are very important for the translation of metabolomic research into clinical practice. 
An interesting example of this application is a collaborative study by systems biology 
researchers and Biocrates investigating a diabetes mouse model 224 employing a proprietary 
kit of reagents including all required reactants, standards and protocols to quantitatively 
determine over 800 endogenous metabolites by LC-MS/MS including: 18 amino acids; 50 
reducing mono-, di-, and oligosaccharides, uronic acid, and N-acetylglucosamine; 16 
acylcarnitines; 5 hydroxyacylcarnitines; 5 dicarboxylacylcarnitines; free carnitine; and 707 
lipids. These lipids were subdivided into 82 different ceramides and glucosylceramides, 110 
different sphingomyelins and sphingomyelin derivatives, 95 glycero-phosphatidic acids, 85 
glycero-phosphatidylcholines, 103 glycero-phosphatidylethanolamines, 11 glycero-
phosphatidylglycerols, 177 glycero-phosphatidylinositols, glycero-phosphatidylinositol-
bisphosphates and -triphosphates, and 44 glycero-phosphatidylserines. Glycero-
phospholipids were further differentiated with respect to the presence of ester and ether 
bonds in the glycerol moiety. Using these kits and flow injection analysis (FIA)-MS/MS 
(SRM) researchers correlated plasma levels of analytes with diabetes treatments; accurate 
concentrations were derived from the use of isotopically labeled internal standards (ISs) 
included in the kits. Metabolite concentrations and ratios of concentrations were derived 
and subjected to unsupervised statistical analysis revealing novel diabetic metabolic 
phenotypes and the impact medication has on them. Many metabolites were oppositely 
impacted by treatment which reduced noise in the data to reveal new potential biomarkers 
of diabetes. This study was subsequently extended to human subjects 225 comparing the 
Biocrates kit results to other approaches using a cohort of 100 subjects comprising 40 
individuals with self-reported diabetes and 60 controls. The other LC-MS approach in this 
study was a proprietary workflow undertaken by Metabolon as well as an NMR study of 
the same samples done by Chenomx. In this pilot study a total of 482 metabolites were 
quantified. The results of this human trial were far less clear than those using the inbred 
murine subjects of the above earlier study for a variety of reasons including heterogeneity of 
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the human subjects with respect to genetic and environmental factors including varying 
degrees of glycemic control. The authors concluded that this multi-platform approach to the 
metabolome-wide analyses of diabetes in a general population was helpful in the 
identification of a series of known, and also some novel, deregulated metabolites that 
associate with diabetes under sub-clinical conditions in the general population. However, 
given the above limitations they observed that a much larger cohort of subjects would be 
necessary. 
In related articles by the same authors 226-227 human genotypes were evaluated against 
metabolomic data creating what the authors deemed as the first genome-wide association 
(GWA) study using metabolic traits as phenotypic traits. In these studies 363 serum 
metabolites from 284 male subjects who were participants in the KORA study 228 were 
rigorously quantitated using the Biocrates kits and (FIA)-MS/MS (SRM). In parallel, single 
nucleotide polymorphisms (SNP’s) were measured using gene-expression chips and 
correlated with the metabolomic data. Genetically determined variants in the metabolic 
phenotype (so called “metabotype”) were observed and enhanced using ratios of 
metabolites with opposite correlations with genotypes. Using this approach, almost 30% of 
genetic variability correlated with the metabolic data with high statistical significance. The 
authors conclude that the investigation of the genetically determined metabotypes in their 
biochemical context may help to better understand the pathogenesis of common diseases 
and gene-environment interactions. These findings could result in a step toward 
personalized health care and early nutritional or other life-style interventions based on a 
combination of genotyping and metabolic characterization. 
The above examples of metabolomic applications featured the use of mainly triple 
quadrupole MS/MS systems, the commonly accepted “workhorse” of quantitative 
bioanalysis. Over the last 20 years the performance of the triple quad platform has risen 
steadily due to the incorporation of new technologies and larger, more efficient pumping 
systems. In fact, like Moore’s Law for computing, the performance of the triple quad 
platform increased by about an order of magnitude every 2 to 3 years more or less in a linear 
fashion until the last 5 years or so when the triple quad began to asymptotically reach its 
maximum performance with respect to signal-to-noise and limits of detection. 
As the triple quad platform begins to mature technologically, other areas of mass 
spectrometer performance are beginning to be exploited in the market; specifically there has 
been a rapid evolution of performance in the area of mass resolving power and mass 
accuracies. This started with the development of the hybrid MS technologies based upon 
quadrupoles and time-of-flight systems, the so called Q-ToF instruments, as well as the 
introduction of linear ion-traps coupled to Fourier transform mass spectrometers (LTQ-FT-
MS systems) and its successor the ion-trap coupled to an Orbitrap system (LTQ-Orbitrap 
systems). These MS/MS systems are capable of high mass accuracies (1-2 ppm) and high 
mass resolutions (20,000 to 300,000 m/Δm) which greatly enhances analytical specificity. 
Generally these hybrid systems are very large, expensive and quite difficult to operate 
making their incorporation into routine clinical diagnostics quite limited. However, recently 
lower cost benchtop versions of the Orbitrap instruments are beginning to appear 229-231. The 
significance of this new type of high resolution/mass accuracy (HRMA) system is just 
beginning to be appreciated since the specificity of HRMA of a single MS system could rival 
that of lower resolution MS/MS systems like the triple quadrupole. The simplicity of a 
single mass analyzer versus MS/MS could provide the impetus to use benchtop HRMA 
systems for routine bioanalytical assays instead of MS/MS. 
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One recent study that exemplifies the use of this technology in metabolomics was recently 
published by Volmer, et.al. 232 where lipids extracted from plasma samples for a cohort of 10 
healthy volunteers were analyzed by UHPLC-MS on a benchtop Orbitrap system. About 240 
separate data analyses were undertaken to develop a statistically meaningful data set 
obtained using 50,000 resolution, and mass accuracies typically well below 2.5 ppm. Like 
previous lipidomic studies 233 Volmer found that setting m/z ion-extraction windows to 
≤2.5 ppm provided unambiguous lipid identification based upon elemental composition. 
Moreover, the re-constructed ion chromatograms were used for quantitation without 
significant isobaric interferences using the analyzer constraints of 50,000 resolution and ~1–2 
ppm mass accuracy. This large data set was subjected to unsupervised statistical analysis 
and demonstrated the ability to differentiate subjects’ plasma samples and to also pick out 
those samples enriched with a particular endogenous or exogenous analyte. The study 
demonstrated that, with high resolving powers and mass accuracies, both targeted and 
untargeted data analysis can be accomplished on the same data set. Another recent example 
of the application of this technology was published by Rabinowitz, et.al. 234 involving the 
UHPLC-MS analysis of anionic metabolites in yeast extract identifying 137 metabolites in a 
single experiment. This type of platform could be especially useful for metabolomic studies 
involving human subjects where high numbers of analytes must be rigorously quantitated 
in a single run but with sufficient flexibility to be able to provide information on unexpected 
analytes such as exogenous compounds and their metabolites that may be present due to 
environmental factors (e.g. disease treatment with pharmaceuticals). The translation of the 
Orbitrap from a research validation tool to a routine instrument for clinical diagnostic 
measurements is inevitable given the analytical power of this novel technology and the 
results that have been published to date. 
5. Conclusion 
The use of tandem mass spectrometry is well documented in the clinical laboratory. In 
particular, the development of atmospheric pressure ionization techniques to perform 
LC/MS has allowed the clinical chemist to address new areas of research and drastically 
improve the quality of clinical assays due to higher specificity and better sensitivity than 
other approaches. The main draw back to clinical applications of LC/MS/MS is the high 
initial cost and the need for dedicated highly trained personnel to run and maintain the 
instruments. The result is that centralized laboratories, either CROs or large medical 
facilities, where samples are sent for analysis are usually needed in order to take advantage 
of the emerging technologies. As our understanding of the use of LC/MS/MS and the 
impact of analyzing biological matrices improves, and mass spectrometers become more 
and more user friendly, the development of a fully automated clinical analyzer should be 
possible. However, until an LC/MS/MS clinical analyzer is commercially available, the use 
of LC/MS/MS in the clinic will remain a specialized tool available by out-sourcing or 
development core facilitates. 
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